Pharma Financial Statement Exclusions Raise Eyebrows

By Torrey and Gray | May 4, 2022

It was recently reported that BIOGEN, and potentially several other big Pharma companies have some explaining to do when it comes to accounting for (or apparently failing to account for) certain payments to the companies related to stock buyback schemes.  In a letter from the SEC to the CFO of BIOGEN from March 2021, they…

Read More